Jupiter Neurosciences (JUNS) Share-based Compensation (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Share-based Compensation of -$409158.0 for Q4 2025, down 145.78% year-over-year from $893781.0 in Q4 2024, and down 204.99% quarter-over-quarter from $389707.0 in Q3 2025.
Jupiter Neurosciences (JUNS) Share-based Compensation (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Share-based Compensation for 3 consecutive years, with -$409158.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation fell 145.78% year-over-year to -$409158.0; the TTM figure through Dec 2025 stood at $1.3 million (up 40.48% YoY), while the FY2025 annual figure was $1.5 million, up 72.99% from the prior year.
- Share-based Compensation slipped to -$409158.0 in Q4 2025 per JUNS's latest filing, from $389707.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $893781.0 in Q4 2024 and bottomed at -$632300.0 in Q3 2024.
- Historically, Share-based Compensation has averaged $209926.9 across 3 years, with a median of $381233.0 in 2025.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 319.22% — and 2025, when it tumbled 145.78%.
- Jupiter Neurosciences' Share-based Compensation stood at $213203.0 in 2023, then soared by 319.22% to $893781.0 in 2024, then sank by 145.78% to -$409158.0 in 2025.
- Business Quant data shows JUNS's Share-based Compensation at -$409158.0 in Q4 2025, $389707.0 in Q3 2025, and $420576.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | 1.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -409,158.00 |
| Dec 31, 2025 | -409,158.00 |
| Sep 30, 2025 | 389,707.00 |
| Sep 30, 2025 | 389,707.00 |
| Jun 30, 2025 | 420,576.00 |
| Jun 30, 2025 | 420,576.00 |
| Mar 31, 2025 | 381,233.00 |
| Mar 31, 2025 | 381,233.00 |
| Dec 31, 2024 | 893,781.00 |
| Dec 31, 2024 | 893,781.00 |
| Sep 30, 2024 | -632,300.00 |
| Sep 30, 2024 | -632,300.00 |
| Jun 30, 2024 | 532,300.00 |
| Jun 30, 2024 | 532,300.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 213,203.00 |
| Dec 31, 2023 | 213,203.00 |